New antiviral agents for the therapy of chronic hepatitis B virus infection

Intervirology

Volumn 42, Issue 2-3, 1999, Pages 125-144

  Zoulim, Fabien ^a,b   Trepo, Christian ^a  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

Author keywords

Antiviral therapy; Chronic hepatitis B; Hepadnaviridae; Hepatitis B virus; Nucleoside analogs; Viral resistance

Indexed keywords

3' O BENZYLTRIFLURIDINE; ACICLOVIR; ADEFOVIR; ADENOSINE DERIVATIVE; CIDOFOVIR; CYCLOPENTYLGUANOSINE; DIDANOSINE; DNA POLYMERASE; DNA VACCINE; FAMCICLOVIR; FIALURIDINE; FOSCARNET; GANCICLOVIR; LAMIVUDINE; LOBUCAVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; STAVUDINE; UNCLASSIFIED DRUG; VALACICLOVIR; VIDARABINE PHOSPHATE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DRUG DEVELOPMENT; DRUG RESISTANCE; GENE MUTATION; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; LACTIC ACIDOSIS; LONG TERM CARE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVIEW; VIRUS REPLICATION;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; VIRUS REPLICATION;

EID: 0032884013     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024972     Document Type: Review

References (168)

1. Niederau C, Heintges T, Lange S, Goldmann G, Niederau C, Mohr L, Haussinger D: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
2. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-356.
3. Trépo C, Jezek P, Atkinson G, Boon R: Efficacy of famciclovir in chronic hepatitis B: Results of a dose-finding study (abstract 247). Hepatology 1996;24:188A.
4. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl Med 1995;333:1657-1661.
5. Fontana RJ, Lok ASF: Combination therapy for chronic hepatitis B. Hepatology 1997;26: 234-237.
6. Summers J: Three recently described animal virus models for human hepatitis B virus. Hepatology 1981;1:179-183.
7. Nassal M: Hepatitis B virus replication: Novel roles for virus-host interactions. Intervirology 1999;42:100-116.
8. Summers J, Mason WS: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415.
9. Seeger C, Ganem D, Varmus HE: Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986;232:477-484.
10. Tuttleman J. Pourcel C, Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 1986;47:451-460.
11. Schaller H, Fischer M: Transcriptional control of hepadnavirus gene expression: in Mason WS, Seeger C (eds): Current Topics in Microbiology and Immunology. Hepadnaviruses. Molecular Biology and Pathogenesis. Berlin, Springer, 1991, pp 41-60.
12. Kay A, Mandart E, Trepo C, Galibert F: The HBV HBx gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J 1985;4:1287-1292.
13. Kuroki K, Cheung R, Marion P, Ganem D: A cell surface protein that binds avian hepatitis B virus particles. J Virol 1994;68:2091-2096.
14. Mason W: The problem of antiviral therapy for chronic hepadnavirus infection. J Hepatol 1993:17(suppl 3):S137-S142.
15. Seeger C, Mason W: Hepadnavirus replication and approaches to antiviral therapy: in Doerfler W, Bohm O (eds): Virus strategies. New York, Wiley, 1993, chapt 4, pp 77-93.
16. Hu J, Seeger C: Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 1996;93:1060-1064.
17. Wang G, Zoulim F, Leber E, Kitson J, Seeger C: The role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J Virol 1994;68:8437-8442.
18. Zoulim F, Seeger C: Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994;68:6-13.
19. Wang G, Zoulim F, Leber E, Seeger C: An RNA-protein interaction is required for enzymatic activity of the hepadnavirus reverse transcriptase (abstract). Molecular Biology of Hepatitis B Viruses, Washington, August 1993, p 12.
20. Hantz, O, Borel C, Trabaud C, Zoulim F, Dessolin J, Camplo M, Vlieghe P, Bouygues M, Trépo C, Kraus JL: Selective inhibition of the duck hepatitis B virus by a new class of letraazamacrocycles. Antimicrob Agents Chemother 1997;41:2579-2581.
21. Bartenschlager R, Schaller H: Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992;11:3413-3420.
22. Nassal M: The arginine rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive strand DNA synthesis but not for virus assembly. J Virol 1992;66:4107-4116.
23. Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D: Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature 1990;344:552-555.
24. Hirsch RC, Loeb DD, Pollack JR, Ganem D: Cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol 1991;65:3309-3316.
25. Hino O, Ohtake K, Rogler CE: Features of two hepatitis B virus (HBV) DNA integrations suggest mechanism of HBV integration. J Virol 1989;63:2638-2643.
26. Bruss V, Ganem D: The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA 1991;88:1059-1063
27. Bruss V, Thomssen R: Mapping of a region of the large envelope protein required for hepatitis B virion maturation. J Virol 1994;68:1643-1650.
28. Bruss V, Vieluf K: Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol 1995;69:6652-6657.
29. Bruss V: A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J Virol 1997;71:9350-9357.
30. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, Lansky DM, Jacob GS, Dwek RA: Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998;4:610-614.
31. Schek N, Fisher M, Schaller H: The hepadnaviral X protein: in Mc Lahlan A (ed): Molecular Biology of the Hepatitis B Virus. Boca Raton, CRC Press, 1991, pp 181-192.
32. Chen HS, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, Purcell RH, Miller RH: The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993;67:1218-1226.
33. Zoulim F, Saputelli J, Seeger C: Woodchuck hepatitis virus X protein is required for viral replication in vivo. J Virol 1994;68:2026-2030.
34. Wu T-T, Coates L, Aldrich CE, Summers J, Mason WS: In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175:255-261.
35. Fourel I, Saputelli J, Schaffer P, Mason W: The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J Virol 1994;68:1059-1065.
36. Fourel I, Cullen J, Saputelli J, Aldrich C, Schaffer P, Averett D, Pugh J, Mason W: Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321-8330.
37. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9399.
38. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H: Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402.
39. Sells MA, Zelent AZ, Shvartsman M, Acs G: Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988;62:2836-2844.
40. Sells MA, Chen M, Acs G: Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987;84:1005-1009.
41. Aldrich CE, Coates L, Wu T-T, Newbold J, Tonnant BC, Summers J, Seeger C, Mason WS: In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus. Virology 1989;172: 247-252.
42. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C: Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988;62:4136-4143.
43. Tuttleman JS, Pugh JC, Summers JW: In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol 1986;58:17-25.
44. Chisari F: Hepatitis B virus transgenic mice: Insights into the virus and the disease. Hepatology 1995;22:1316-1325.
45. Nair V, Jahnke T: Antiviral activities of isomeric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob Agents Chemother 1995;39:1017-1029.
46. Bridges E, Cheng Y: Use of novel b-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma: in Boyer JL, Ockner RK (eds): Progress in liver diseases. 1995;13:231-245.
47. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C: Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
48. Chang C-N, Doong S-L, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai C-H, Cheng Y-C: Deoxycytidine deaminase-resistant stereoisomer is the active form of (±) 2',3' dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992;267: 13938-13942.
49. Van Draanen N, Tisdale M, Parry N, Jansen R, Dornsife R, Tuttle J, Averett D, Koszalka G: Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother 1994;38:868-871.
50. Severini A, Liu X-Y, Wilson J, Tyrell D: Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1995; 39:1430-1435.
51. Zoulim F, Dannaoui E, Borel C, Hantz O, Lin T, Liu S, Trépo C, Cheng Y: 2',3'-dideoxy-b-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother 1996;40:448-453.
52. Parker W, Cheng Y: Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 1994; 6:57-61.
53. Rajagopalan P, Boudinot F, Chu C, Tennant B, Baldwin B, Schinazi R: Pharmacokinetics of (-)2',3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob Agents Chemother 1996; 40:642-645.
54. Condreay L, Condreay J, Jansen R, Paff M, Averett D: (-)-Cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother 1996;40:520-523.
55. Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, Linzey D, Frick L, Paff MT, Goulding A, Biron K: In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 1997;41:2076-2082.
56. Lin T, Luo M, Liu M, Pai S, Dutschman G, Cheng Y: Antiviral activity of 2',3'-dideoxy-b-L-5-fluorocytidine (b-L-F-ddC) and 2',3'-dideoxy-b-L-cytidine (b-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 1994;47: 171-174.
57. Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, Chu CK, Trépo C, Cheng YC, Zoulim F: Inhibitory effect of 2'-fluoro-5-methyl-b-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998;42:369-376.
58. Dutschman GE, Bridges EG, Liu S-H, Gullen E, Guo X, Kukhanova M, Cheng Y-C: Metabolism of 2',3'-dideoxy-2',3'-didehydro-b-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus b-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother 1998; 42:1799-1804.
59. Zhu Y-L, Dutschman GE, Liu S-H, Bridges EG, Cheng Y-C: Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-b-L(-)-5-fluorocytidine. Antimicrob Agents Chemother 1998;42:1805-1810.
60. Le Guerhier F, Pichoud C, Chevallier M, Liu SH, Chen SH, Li XY, Trépo C, Cheng YC, Zoulim F: Antiviral activity of a novel L nucleoside analog, b-L-FD4C, in the duck HBV infection model (abstract). Antiviral Res. in press.
61. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, R. BR, Richardson FC, Lewis W, Cote PJ, Korba BE, Gerin JL: Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998;28:179-191.
62. Cui L, Yoon S, Schinazi R, Sommadossi J: Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-b-D-arabinofuranosyl)-5-iodouracil in human. J Clin Invest 1995;95:555-563.
63. Pai S, Liu S, Zhu Y, Chu C, Cheng Y: Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-b-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40: 380-386.
64. Mc Kenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y, Savarese B, Kleiner D, Toskos M, Luciano C, Pruett T, Stotka J, Strau S, Hoofnagle J: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
65. Wang J, Eriksson S: Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-b-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother 1996;40: 1555-1557.
66. Lewis W, Levine E, Griniuvene B, Tankersley K, Colacino J, Sommadossi J, Watanabe K, Perrino F: Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-3597.
67. Fourel I, Hantz O, Watanabe K, Jacquet C, Chomel B, Fox J, Trépo C: Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 1990;34:473-475.
68. Fourel I, Li JS, Hantz O, Jacquet C, Fox JJ, Trépo C: Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and in liver of chronically infected ducks. J Med Virol 1992;37: 122-126.
69. Chu C, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai S, Yao G, Sommadossi J, Cheng Y: Use of 2'-fluoro-5-methyl-b-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995;39:979-981.
70. Liu S-H, Grove KL, Cheng Y-C: Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-b-L-arabmofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998;42:833-839.
71. Wright Witcher J, Boudinot FD, Baldwin BH, Ascenzi MA, Tennant BC, Du JF, Chu CK: Pharmacokinctics of 1-(2-fluoro-5-methyl-b-L-arabinoturanosyl) uracil in woodchucks. Antimicrob Agents Chemother 1997;41:2184-2187.
72. Zoulim F, Trépo C: Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. J Hepatol 1994;21:142-144.
73. Boyd M, Bacon T, Sutton D, Cole M: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31:1238-1242.
74. Vere Hodge R, Perkins R: Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989;33:223-229.
75. Earnshaw D, Bacon T, Darlison S, Edmonds K, Perkins R, Vere Hodge R: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1). HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-2757.
76. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S: The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996;40:413-418.
77. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S: In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994;38:719-723.
78. Tsiquaye K, Slomka M, Maung M: Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994;42:306-310.
79. Korba B, Boyd M: Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996;40:1282-1284.
80. Tsiquaye K, Sutton D, Maung M, Boyd M: Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem Chemother 1996;7:153-159.
81. Shaw T, Mok S, Locarnini S: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24:96-102.
82. Dannaoui E, Trépo C, Zoulim F: Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir Chem Chemother 1997;8:38-46.
83. Mason W, Cullen J, Saputelli J, Wu T, Liu C, London W, Lustbader E, Schaffer P, O'Connell A, Fourel I, Aldrich C, Jilbert A: Characterization ot the antiviral activity of 2'-carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994;19: 398-411.
84. Bloomer J, Chan R, Sherman M, Ingraham P, De Hertog D: A preliminary study of lobucavir for chronic hepatitis B (abstract 1199). Hepatology 1997;26(No 4. Pt 2):428A.
85. Heathcote J, Chan R, McHutchinson J, Lee WM, Sherman M, Rutkiewicz V, De Hertog D: A phase 2 multicenter-study of oral lobucavir for treatment of chronic hepatitis B (abstract). Hepatology 1998;28:318A.
86. Fourel I, Gripon P, Hantz O, Cova L, Lambert V, Jacquet C, Watanabe K, Fox J, Guillouzo C, Trépo C: Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: A useful system for antiviral testing. Hepatology 1989;10:186-191.
87. Trépo C, Ouzan D, Fontanges T, Chevallier M, Chossegros P, Degos F, Chevallier P, Hantz O: Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV. J Hepatol 1986;3(suppl 2):S97-S105.
88. Marcellin P, Ouzan D, Degos F, Bréchot C, Metman E, Degott C, Chevallier M, Berthelot P, Trépo C, Benhamou J: Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients. Hepatology 1989;10:328-331.
89. Marcellin P, Pouteau M, Loriot M, Boyer N, Degos F, Cales P, Martinot-Peignoux M, Degott C, Erlinger S, Benhamou J: Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: Comparison of the efficacy in patients with high and low viral replication. Gut 1995;36:422-426.
90. Xiong X, Flores C, Gibbs C, Toole J: Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons (abstract 1211). Hepatology 1997;26(No 4, Pt 2):431A.
91. Heatheote EJ, Jeffers L, Wright T, Sherman M, Perillo R, Sacks S, Carithers R, Rustgi V, Di Bisceglic A, Balan V, Murray A, Rooney J, S, JH: Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo controlled phase II studies (abstract). Hepatology 1998;28:317A.
92. Lai C-L, Ching C-K, Tung AK-M, Li E, Young J, Hill A, Wong BC-Y, Dent J, Wu P-C: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 1997;25:241-244.
93. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man R, Thomas HC: Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-1263.
94. Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lisoos T, Condreay L, Garett L, Rubin M, Brown N: Extended lamivudine retreatment for chronic hepatitis B (abstract 245). Hepatology 1996;24:188A.
95. Honkoop P, de Man RA, Zondervan PE, Schalm SW: Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;17: 103-106.
96. Lai CL, Law YF, Leung NWY, Deslauriers M, Barnard J, Sanathanan L, Gray DF, Condreay LD: Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: Incidence, kinetics of emergence and correlation with disease parameters. Hepatology 1997; 26:522A.
97. Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Barber J, Dent JC, Gray DF: Lamivudine (100 mg od) for one year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: Results of a placebo controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection. Hepatology 1997;26 (No 4, Pt 2):916A
98. Lai CL, Chine RW, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray F: A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
99. Gish R, Lau J, Brooks L, Fang J, Steady S, Imperial J, Garcia-Kennedy R, Esquivel C, Keeffe E: Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996;23:1-7.
100. Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, Dienstag J, Gish R, Villeneuve J, Caldwell S, Brown N, Self P: Long-term lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. Hepatology 1997;26:196A.
101. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs A, Rolles K, McMaster P, Beranck P, Kennedy F, Kibbler H, McPhilips P, Elias E, Dusheiko G: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-1215.
102. Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, Gish R, Dickson R, Adams P, Brown N, Self P: Lamivudine for suppression and/or prevention of hepatitis B when given pre-/post-liver transplantation (OLT). Hepatology 1997;26:526A.
103. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P: Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125: 705-712.
104. Tong S, Li J, Vivitski L, Trépo C: Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 1990;176:596-603.
105. Carman W, Hadziyannis S, Mc Garvey MJ, Jacyna M, Karayiannis P, Makris A, Thomas H: Mutation preventing formation of hepatitis Be antigen in patients with chronic hepatitis B infection. Lancet 1989;ii:588-591.
106. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trépo C: Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
107. Brunetto M, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate M, Manzini P, Capalbo M, Piantino P, Verme G, Bonino F: Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105:845-850.
108. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R, Hawley S, Gray DF: Lamivudine therapy in patients with anti-HBe positive chronic hepatitis B: end of treatment analysis. J Hepatol 1998;28 (suppl 1):43.
109. Main J, Brown J, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, Atkinson G, Thomas H: A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1996;3:211-215.
110. Krüger M, Tillmann H, Trautwein C, Oldhafer K, Boker K, Pichlmayr R, Manns M: Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation. A pilot study (abstract 449). Hepatology 1995; 22:219A.
111. Neuhaus P, Manns M, Atkinson G: Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients (abstract 528). Hepatology 1997;26 (No 4, Pt 2):260A.
112. Saltzman R, Jarewicz R, Boon R: Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38:2454-2457.
113. Krüger M, Böker KHW, Zeidler H, Manns M: Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997;26:935-939.
114. Lau GKK, Liang R, Wu PC, Lee CK, Lim WL, Au WY: Use of famciclovir to prevent HBV reactivation in HbsAg-positive recipients after allogeneic bone marrow transplanlation. J Hepatol 1998;28:359-368.
115. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Tennant B, Frick L, Averett D, Condreay LD, Jilbert AR: Lamivudine therapy of WHV-infeeted woodchucks. Virology 1998;245:18-32.
116. Luscombe C, Pedersen J, Uren E, Locarnini S: Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect of intrahepatic-viral DNA, RNA, and protein expression. Hepatology 1996;24: 766-773.
117. Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S: Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998; 42:2132-2137.
118. Honkoop P, De Man RA, Heijtink RA, Schalm SW: Hepatitis B reactivation after lamivudine. Lancet 1995;346:1156-1157.
119. Cirelli R, Herne K, McCrary M, Lee P, Tyring S: Famciclovir: Review of clinical efficacy and safety. Antiviral Res 1996;29:141-151.
120. Honkoop P, de Man RA, Scholte HR, Zondervan PE, Van Den Berg JWO, Rademekers LHPM, Schalm SW: Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997;26:211-215.
121. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
122. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711-713.
123. Richman DD: Drug resistance and its implications in the management of HIV infection. Antiviral Ther 1997;2 (suppl 4):41-58.
124. Arts E, Wainberg M: Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996;40:527-540.
125. Fischer KP, Tyrell DLJ: Generation of duck hepal itis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine((-)-b-L-2',3'-dideoxy-3'-thiacytidine) in vitro. Antimicrob Agents Chemother 1996;40:1957-1960.
126. Locarnini SA, Aye TT, Shaw T, De Man R, Angus PW, Mc Caughan GW, Bartholomeusz A: The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation. Hepatology 1997;26:958A.
127. Shields PL, Ling R, Harrison T, Boxall E, Elias E, Mutimer DJ: Management and outcome of lamivudine resistant hepatitis B virus infection after liver transplantation (abstract 527). Hepatology 1997;26(No 4, Pt 2): 260A.
128. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW: Lamivudine resistance in immunocompetent chronic hepatitis B: Incidence and patterns. J Hepatol 1997;26:1393-1395.
129. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, Mc Millan J, Angus P, Locarnini S: Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997: 1148-1153.
130. Bartholomeusz A, Locarnini S: Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997;5:123-124.
131. Bartholomeusz A, Groenen LC, Locarnini SA: Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology 1997;40:337-342.
132. Tillmann HL, Trautwein C, Bock T, Glowenka M, Krüger M, Böker K, Jäckel E, Pichlmayr R, Condreay L, Bruns I, Deslauriers M, Gauthier J, Manns M: Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 1997;26:1202A.
133. Zoulim F, Pichoud C, Wang Z, Aguesse-Germon S, Trépo C: Hepatitis B virus genome variability during famciclovir therapy (abstract 1200). Hepatology 1997;26(No 4, Pt 2): 428A.
134. Norder H, Couroucé A-M, Magnius L: Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
135. Carman W: The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepatitis 1997;4:11-20.
136. Xiong Y, Eickbush T: Origin and evolution of retroelements based upon their reverse transcriptase sequence. EMBO J 1990;9:3353-3362.
137. Toh H, Hayashida H, Miyata T: Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983;305:827-829.
138. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256: 1783-1790.
139. Radziwill G, Tucker W, Schauer H: Mutational analysis of the hepatitis B virus P gene product: Domain structure and RNAseH activity. J Virol 1990;64:613-620.
140. Wang GH, Seeger C: The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell 1992;71:633-670.
141. Chang L-J, Hirsch RC, Ganem D, Varmus HE: Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol 1990;64:5553-5558.
142. Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, Mc Millan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW: Characterization of human immunodeficiency viruses resistant ot oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
143. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-5656.
144. Bartholomew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendahl H, Condreay L, Tzakis A, Schiff A, Brown N: Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
145. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R: Line Probe Assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
146. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrell DLJ, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27: 1670-1677.
147. Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
148. Back NKT, Berkhout B: Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1997;41:2484-2491.
149. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, Berkhout B: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-4049.
150. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-1285.
151. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyamo Y, Koike H, Kobayashi M, Koida I, Arase Y, Saito S, Murashima N, Ikeda K, Kumada H: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-take-over by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
152. Fu L, Cheng Y-C: Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998;55:1567-1572.
153. Seignères B, Pichoud C, Si Ahmed S, Hantz O, Trépo C, Zoulim F: Non response to famciclovir therapy in immune competent patients with chronic hepatitis B is associated with complex variability of the polymerase gene (abstract). Hepatology 1998;28:586A.
154. Zoulim F: Improving hepatitis B virus therapy - New inhibitors of reverse transcriptase. Int Antiviral News 1997;5:110-112.
155. Aguesse S, Dannaoui E, Wang Z, Boulay A, Borel C, Schinazi R, Cheng Y, Trépo C, Zoulim F: An in vitro assay for the determination of the mechanism of inhibition of hepatitis B virus replication by nucleoside analogs and non nucleoside inhibitors. Proceedings of the IX Triennial International Symposium of Viral Hepatitis and Liver Disease, in press.
156. Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-225.
157. Innaimo SF, Seller M, Bisucchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-1448.
158. Marinos G, Naoumov N, Williams R: Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996;24: 991-995.
159. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, McPhilipps P, Johnson M, Williams R, Elias E, Schalm S: Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study. J. Hepatol 1998;28:923-929.
160. Heathcote J, Sehalm SW, Cianciara J, Farrell G, Feinman V, Shermann M, Dhillon AP, Moorat AE, Gray DF: Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol 1998; 28(suppl 1):43.
161. Marques A, Lau D, McKenzie R, Strauss S, Hoofnagle J: Combination therapy with famciclovir and interferon alpha for the treatment of chronic hepatitis B. J Infect Dis 1998; 178:1483-1487.
162. Koziel MG, Liang TJ: DNA vaccines and viral hepatitis: Are we going around in circles. Gastroenterology 1997;112:1410-1414.
163. Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel M: Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: A possible way of circumventing 'nonresponse to HBsAg'. J Med Virol 1992;39:67-74.
164. Pol S, Driss F, Michel M, Nalpas B, Berthelot P. Bréchot C: Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344:342.
165. von Weizsäcker G, Wieland S, Köck J, Offensperger W-B, Offensperger S, Moradpour D, Blum HE: Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997;26:251-255.
166. Offensperger W, Offensperger S, Walter E, Teubner K, Igloi G, Blum H, Gerok W: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993;12:1257-1262.
167. Scaglioni P, Melegari M, Takahashi M, Roy Chowdhury J, Wands J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996;24: 1010-1017.
168. von Weizsäcker F, Blum H, Wands F: Cleavage of hepatitis B virus RNA by three ribozymes transcribed from single DNA template. Biochem Biophys Res Commun 1992; 189:743-748.